AVTEAerovate Therapeutics, Inc.

Nasdaq aerovatetx.com


$ 1.89 $ 0.02 (1.06 %)    

Friday, 13-Sep-2024 15:59:42 EDT
QQQ $ 474.86 $ 2.12 (0.45 %)
DIA $ 414.87 $ 2.97 (0.72 %)
SPY $ 561.82 $ 2.92 (0.52 %)
TLT $ 100.40 $ 0.27 (0.27 %)
GLD $ 238.66 $ 2.35 (0.99 %)
$ 1.9
$ 1.89 x 1,410
-- x --
-- - --
$ 1.25 - $ 32.42
255,293
na
54.85M
$ 1.04
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-12-2024 06-30-2024 10-Q
2 05-13-2024 03-31-2024 10-Q
3 03-25-2024 12-31-2023 10-K
4 11-13-2023 09-30-2023 10-Q
5 08-14-2023 06-30-2023 10-Q
6 05-15-2023 03-31-2023 10-Q
7 03-29-2023 12-31-2022 10-K
8 11-14-2022 09-30-2022 10-Q
9 08-15-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-30-2022 12-31-2021 10-K
12 11-15-2021 09-30-2021 10-Q
13 08-16-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 aerovate-therapeutics-to-explore-strategic-alternatives-which-may-include-but-are-not-limited-to-an-acquisition-merger-reverse-merger-business-combination-liquidation-or-other-transaction

Aerovate Therapeutics, Inc. (NASDAQ:AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 p...

 evercore-isi-group-downgrades-aerovate-therapeutics-to-in-line-lowers-price-target-to-2

Evercore ISI Group analyst Liisa Bayko downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Outperform to In-Line and lowers ...

 guggenheim-downgrades-aerovate-therapeutics-to-neutral

Guggenheim analyst Vamil Divan downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

 wells-fargo-downgrades-aerovate-therapeutics-to-equal-weight-lowers-price-target-to-2

Wells Fargo analyst Tiago Fauth downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Overweight to Equal-Weight and lowers th...

 td-cowen-downgrades-aerovate-therapeutics-to-hold

TD Cowen analyst Joseph Thome downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold.

 jefferies-downgrades-aerovate-therapeutics-to-hold-lowers-price-target-to-2

Jefferies analyst Eun Yang downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Hold and lowers the price target from ...

 btig-downgrades-aerovate-therapeutics-to-neutral

BTIG analyst Julian Harrison downgrades Aerovate Therapeutics (NASDAQ:AVTE) from Buy to Neutral.

 why-is-small-cap-heart-disease-focused-aerovate-therapeutics-stock-plummeting-on-monday

Aerovate Therapeutics shares dropped 90.4% following the release of Phase 2b trial results for AV-101 for pulmonary arterial hy...

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

 aerovate-therapeutics-presents-baseline-data-from-phase-2b-portion-of-impahct-trial-at-ats-2024-international-conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study ...

 wedbush-reiterates-outperform-on-aerovate-therapeutics-maintains-41-price-target

Wedbush analyst Laura Chico reiterates Aerovate Therapeutics (NASDAQ:AVTE) with a Outperform and maintains $41 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION